Ind-Swift Laboratories Announces Land Sale Deal and Reports Quarter Results

Ind-Swift Laboratories Announces Land Sale Deal and Reports Quarter Results​

Ind-Swift Laboratories Limited has announced that its Board of Directors approved several key decisions, including the sale of a non-operational land parcel and the release of unaudited financial results for the quarter ended June 30, 2026.

The company confirmed the approval to sell a piece of land situated in Village Behra, Derabassi, Punjab. The land parcel measures approximately 40 Bighas (about 10 acres). Ind-Swift Laboratories will receive a total consideration of ₹17.50 Crore for this disposal.

The sale transaction is expected to be completed over a period of nine months, subject to the terms and conditions of the agreement. The company stated that the land was originally purchased for setting up a manufacturing facility but is now being sold as it was found unsuitable for establishing the Finished dosages facility based on applicable International regulatory/registration requirements.

Q2 FY2026 Financial Performance Highlights​

Ind-Swift Laboratories reported both standalone and consolidated unaudited financial results for the quarter ended June 30, 2026. The company noted that it achieved an EBITDA of ₹33.32 Crores during the quarter, compared to an EBITDA of ₹8.44 Crores and a Standalone Net Profit of ₹8.12 Crores in the corresponding quarter of the previous financial year.

The unaudited results were reviewed by the Audit Committee and approved by the Board of Directors. The company's operations are exclusively within the Pharmaceutical Business segment.

Key performance figures for the quarter ended June 30, 2026, across both Standalone and Consolidated accounts are detailed below:

Operational Updates and Subsidiary Details​

The consolidated financial results incorporate the performance of several subsidiaries and joint ventures within the Group structure. These entities include:

• Subsidiaries: Fortune (India) Constructions Ltd., MJM Remedies Private Limited, Ind Swift Laboratories Inc. USA, ISLL Middle East LLC-FZ, and Ind Swift India Ltd (Kenya).
• Joint Ventures: Indis Healthcare LLP and Capital Strikers LLP.

For the quarter ended June 30, 2026, the consolidated results showed a Total Comprehensive Income of ₹2476.64 Lakhs.

The company also provided additional context regarding exceptional items for the quarter:

• Exceptional items recorded for the current quarter were ₹23.58 Lakhs.
• For the previous quarter (March 31, 2026), the exceptional items stood at ₹515.24 Lakhs.
• The financial year ended March 31, 2026, recorded exceptional items of ₹1,100.64 Lakhs, relating to balances written back or written off due to amounts no longer payable or receivable.

INDSWFTLAB Stock Price Movement​

Ind-Swift Laboratories Limited saw its stock climb today, settling at ₹237.24 after the equity rallied by 4.64%. The security traded in a range of ₹228.3 to ₹240.75 and recorded a volume of 1.03 million shares during the session.